Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMN1ZEU)

Drug Name
Radiosensitizer gene therapy Drug Info
Synonyms Radiosensitizer gene therapy (prostate cancer)
Indication
Disease Entry ICD 11 Status REF
Pancreatic cancer 2C10 Phase 3 [1]
Cross-matching ID
TTD Drug ID
DMN1ZEU

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Thymidine kinase 1 (TK1) TTP3QRF KITH_HUMAN Inhibitor [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Thymidine kinase 1 (TK1) DTT TK1 5.524 5.296 5.963 6.272
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Pancreatic cancer
ICD Disease Classification 2C10
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Thymidine kinase 1 (TK1) DTT TK1 1.14E-03 0.26 0.75
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 Clinical pipeline report, company report or official report of Advantagene.
2 Pronounced antitumor effects and tumor radiosensitization of double suicide gene therapy. Clin Cancer Res. 1997 Nov;3(11):2081-8.